Loading…
Denali Therapeutics Inc. is projected to rise to $28.67 by 2027, a +18% move from its current price of $24.35. DNLI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $23.74 | $24.35 | $24.98 | +0.01% |
| Aug 2 | $23.49 | $24.36 | $25.25 | +0.02% |
| Aug 3 | $23.31 | $24.36 | $25.46 | +0.03% |
| Aug 4 | $23.15 | $24.36 | $25.63 | +0.04% |
| Aug 5 | $23.01 | $24.36 | $25.79 | +0.05% |
| Aug 6 | $22.89 | $24.37 | $25.93 | +0.06% |
| Aug 7 | $22.78 | $24.37 | $26.07 | +0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $22.78 | $24.37 | $26.07 | +0.07% |
| Week 2 | $22.17 | $24.39 | $26.82 | +0.14% |
| Week 3 | $21.71 | $24.40 | $27.43 | +0.22% |
| Week 4 | $21.34 | $24.42 | $27.95 | +0.29% |
| Week 5 | $21.02 | $24.44 | $28.41 | +0.36% |
| Week 6 | $20.73 | $24.46 | $28.85 | +0.43% |
| Week 7 | $20.47 | $24.47 | $29.25 | +0.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Denali Therapeutics Inc. is a healthcare company that discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. Its portfolio includes programs such as Eclitasertib (SAR443122/DNL758), a RIPK1 inhibitor for peripheral inflammatory diseases, and BIIB122/DNL151, a LRRK2 inhibitor program for Parkinson’s disease.
The company also pursues TAK-594/DNL593 for frontotemporal dementia-granulin, DNL126 for MPS IIIA (Sanfilippo Syndrome A), DNL310 Tividenofusp alfa for MPS II (Hunter Syndrome), and Enzyme TransportVehicle (TV) programs like DNL952 for Pompe disease, DNL111 for Parkinson’s and Gaucher diseases, and DNL622 for Hurler syndrome (MPS I).
Denali Therapeutics was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. It was incorporated in 2013 and is headquartered in South San Francisco, California.
These details frame Denali as a focused biopharmaceutical company with a diversified pipeline spanning neurodegenerative and lysosomal storage targets, backed by a history of corporate restructuring and location in a major biotech hub.”
Denali Therapeutics Inc. (DNLI) is a healthcare stock currently priced at $23.02 with a market cap of $3.65B, and it ranks 1619 by market position. The stock sits within a volatile landscape, reflecting a broad development-stage biotechnology profile.
The near-term technical picture shows bullish sentiment, with the price trading above key moving averages and facing a defined support and resistance framework. The 30-day range extends from $18.61 to $28.48, outlining a dynamic window for near-term movement. The stock’s RSI is 40, and the SMA50 is $21.88 while the SMA200 is $19.33, indicating a price level that sits above both moving averages.
From a longer horizon, the forecast map projects a substantial rise in average prices from 2026 onward, with DNLI expected to move through multiple growth milestones. The projected path includes a progression from a 2026 avg of $23.02 toward higher averages across the 2030s, 2040s, and into 2050, accompanied by rising ROI figures that illustrate potential long-term upside.”
A major floor 25.7% below — a decisive break under it would weaken the trend.
The nearest floor, 7.0% below — buyers have tended to step in here.
The nearest ceiling, 11.7% above — a clean break opens room to run.
A major ceiling 20.3% above — clearing it would confirm fresh momentum.
Key DNLI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DNLI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $23.79 | Buy | $23.93 | Buy |
| MA 10 | $23.60 | Buy | $23.87 | Buy |
| MA 20 | $24.42 | Sell | $23.92 | Buy |
| MA 50 | $22.80 | Buy | $23.07 | Buy |
| MA 100 | $21.35 | Buy | $21.81 | Buy |
| MA 200 | $19.80 | Buy | $20.34 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.90 | Neutral |
| Stoch RSI (14) | 47.15 | Neutral |
| CCI (20) | -3.46 | Neutral |
| Williams %R (14) | -55.61 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | 7.51 | Buy |
| Bollinger %B (20,2) | 0.49 | Neutral |
| Stochastic %K (14) | 44.39 | Neutral |
| TRIX (15) | 0.15 | Buy |
| Awesome (5,34) | -0.43 | Sell |
| Ultimate (7,14,28) | 54.77 | Neutral |
| Momentum (10) | 1.62 | Buy |
| Aroon Osc (25) | -12.00 | Sell |
| Hull MA (9) | 24.11 | Buy |
| ADX (14) | 17.26 | Neutral |
| ATR (14) | 0.56 | Info |
The 30-day technical picture shows a bullish tilt based on the available signals. The stock’s sentiment is listed as BULLISH, with RSI(14) at 40, suggesting room for momentum without overbought pressure.
Denali’s price sits above the SMA50 of $21.88 and the SMA200 of $19.33, reinforcing a constructive near-term frame. Support is indicated at $19.35 and resistance at $27.21, delineating a clear trading range in the near term. The explicit 30-day range spans from $18.61 to $28.48, illustrating the volatility and potential paths over the coming weeks.”
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.02 | $24.35 | $32.46 | 0% | Neutral | |
| $23.00 | $28.67 | $37.70 | +18% | Neutral | |
| $28.58 | $36.56 | $49.80 | +50% | Bullish | |
| $34.07 | $44.55 | $62.37 | +83% | Bullish | |
| $40.08 | $53.41 | $76.54 | +119% | Bullish | |
| $43.83 | $59.41 | $86.88 | +144% | Bullish | |
| $43.51 | $59.93 | $89.25 | +146% | Bullish | |
| $49.28 | $68.91 | $104.32 | +183% | Bullish | |
| $54.17 | $76.83 | $118.08 | +216% | Bullish | |
| $60.91 | $87.56 | $136.48 | +260% | Bullish | |
| $84.05 | $128.47 | $212.39 | +428% | Bullish | |
| $176.04 | $298.78 | $538.35 | +11.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $16.02 | $24.35 | $28.40 | +0.00% |
| August 2026 | $20.86 | $24.44 | $29.29 | +0.38% |
| September 2026 | $20.81 | $24.58 | $29.83 | +0.56% |
| October 2026 | $21.63 | $25.71 | $31.50 | +4.59% |
| November 2026 | $22.10 | $26.40 | $32.62 | +2.71% |
| December 2026 | $21.73 | $26.09 | $32.46 | -1.20% |
Click any year to see its month-by-month DNLI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DNLI to range from $16.02 to $32.46 through 2026. The $24.35 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The DNLI price prediction for 2027 points to an average of $28.67 (low $23.00, high $37.70) — a potential gain of +18% on today's $24.35. A consolidation phase looks the most probable path here.
In 2028, DNLI is projected to trade between $28.58 and $49.80, averaging $36.56 — a potential gain of +50% from today's $24.35. That is up +28% on the projected 2027 average. Momentum favours further upside here.
Denali Therapeutics Inc.'s 2029 outlook centres on $44.55, within a $34.07 to $62.37 range. That is up +22% on the projected 2028 average. That marks a +83% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, DNLI could reach as high as $76.54, with a base case around $53.41 and support toward $40.08 — roughly +119% from $24.35. Momentum favours further upside here.
Expect DNLI to range from $43.83 to $86.88 through 2031. The $59.41 average target implies a +144% move from current prices. That is up +11% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The DNLI price prediction for 2032 points to an average of $59.93 (low $43.51, high $89.25) — a potential gain of +146% on today's $24.35. Momentum favours further upside here.
In 2033, DNLI is projected to trade between $49.28 and $104.32, averaging $68.91 — a potential gain of +183% from today's $24.35. That is up +15% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Denali Therapeutics Inc.'s 2034 outlook centres on $76.83, within a $54.17 to $118.08 range. That is up +11% on the projected 2033 average. That marks a +216% change versus current levels. Momentum favours further upside here.
By 2035, DNLI could reach as high as $136.48, with a base case around $87.56 and support toward $60.91 — roughly +260% from $24.35. Buyers look set to stay in control over this stretch.
Expect DNLI to range from $84.05 to $212.39 through 2040. The $128.47 average target implies a +428% move from current prices. That is up +47% on the projected 2035 average. Momentum favours further upside here.
The DNLI price prediction for 2050 points to an average of $298.78 (low $176.04, high $538.35) — a potential gain of +11.3x on today's $24.35. Buyers look set to stay in control over this stretch.
Investing $1,000 in DNLI today (≈ 41.067762 DNLI) could be worth
$12,270.16
+$11,270.16 (+1127%) by 2050 · US Dollar
Based on the average projected DNLI price of $298.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DNLIwould be worth at today's price.
$1,000 invested in DNLI on Jul 30, 2025 (≈ 73.152889 DNLI) would be worth
$1,781.27
+$781.27 (+78.1%) today · 1.78× · US Dollar
Based on a DNLI entry price of $13.67 vs. today's $24.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $23.42 | $1,039.71 | +4.0% |
| 1 month ago | $25.72 | $946.73 | -5.3% |
| 3 months ago | $18.3 | $1,330.6 | +33.1% |
| 6 months ago | $21.74 | $1,120.06 | +12.0% |
| 1 year ago | $13.67 | $1,781.27 | +78.1% |
| All time (5.0y) ago | $50.48 | $482.37 | -51.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DNLI forecast.
Our base-case forecast reaches $49.00 around 2030.
Implied market cap at $49.00: $7.78B
The multi-year forecast outlines a bullish trajectory for Denali, with the 2026 average price at $23.02 and a max of $31.09 (min $16.02), and a 0 ROI for that year. By 2027, the average climbs to $26.66 with a max of $36.22 and a 15.8 ROI, continuing a pattern of upside into 2028 (avg $34.06, max $48.31, ROI 48). The path extends through 2030 (avg $50.93, max $76.78, ROI 121.3) and 2035 (avg $78.66, max $131.05, ROI 241.7), signaling strengthening upside momentum.
By 2040, the forecast shows an average of $111.73 with a max of $199.52 and a substantial ROI of 385.4, reflecting a significant long-term uplift. By 2050, the average price is projected at $266.16 with a max of $525.32 and an ROI of 1056.2, supporting a strongly bullish longer horizon. While the near term includes some neutral readings, the longer horizon consistently points to higher values and meaningful upside; risks include the usual biotech development and market dynamics that could alter the trajectory.”
Tap a question to reveal the answer.
2030 avg $50.93; min $36.57; max $76.78; ROI 121.3; sentiment BULLISH.
Forecasts show a path from 2026 avg $23.02 toward higher averages in 2030 and beyond, with 2030 avg $50.93 and 2050 avg $266.16, ROI 121.3 and 1056.2 respectively. These imply upside potential but are not guarantees and depend on multiple factors.
Yes, the 2040 forecast reports an avg of $111.73 and a max of $199.52, which indicates the possibility of exceeding $100 in that horizon.
The 30-day range is $18.61 to $28.48.
Denali Therapeutics Inc. Community Discussion
0Share your Denali Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.